hGH fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-10. Numbers and descriptions here follow the published literature rather than marketing material.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
=== Cannibalism === On 23 July 1988, Gibson ate the flesh of another person in public. Because England does not have a specific law against cannibalism, he legally ate a canapé of donated human tonsils in Walthamstow High Street, London. A year later, on 15 April 1989, he publicly ate a slice of human testicle. When he tried to eat another slice of human testicle as "hors d'oeuvre" at the Pitt International Galleries in Vancouver on 14 July 1989, the police confiscated the testicle. However, the charge of publicly exhibiting a disgusting object was dropped, and two months later he finally ate the piece of human testicle on the steps of the Vancouver court house.
United States: The U.S. government operates border preclearance facilities at several ports and airports in foreign territory. They are staffed and operated by U.S. Customs and Border Protection officers. Travellers pass through the U.S. Immigration and Customs, Public Health, and Agriculture inspections before boarding their aircraft, ship, or train. This process is intended to streamline border procedures, reduce congestion at ports of entry, and facilitate travel between the preclearance location and American airports that are not equipped to handle international travellers. These facilities are present at the majority of major Canadian airports, as well as selected airports in Bermuda, Aruba, the Bahamas, Abu Dhabi and Ireland. Facilities located in Canada accept NEXUS cards and United States Passport cards (land/sea entry only) in place of passports. A preclearance facility is currently being planned at Dubai International Airport. Citizens of the Bahamas who enter United States through either of the two preclearance facilities in that country enjoy an exemption from the general requirement to hold a visa as long as they can sufficiently prove that they do not have a significant criminal record in either the Bahamas or the U.S. All Bahamians applying for admission at a port-of-entry other than the preclearance facilities located in Nassau or Freeport International airports are required to have a valid visa. Preclearance facilities are also operated at Pacific Central Station, the Port of Vancouver, and the Port of Victoria in British Columbia.
persistence 1. The tendency of a moving cell to continue moving in the same direction as previously; that is, even in isotropic environments, there inevitably still exists an inherent bias by which, from instant to instant, cells are more likely not to change direction than to change direction. Averaged over long periods of time, however, this bias is less obvious and cell movements are better described as a random walk. 2. The ability of some viruses to remain present and viable in cells, organisms, or populations for very long periods of time by any of a variety of strategies, including retroviral integration and immune suppression, often in a latent form which replicates very slowly or not at all.
Sources: en.wikipedia.org
Recently, a new technique called NeuCode SILAC, has augmented the level of multiplexing achievable with metabolic labeling (up to 4). The NeuCode amino acid method is similar to SILAC but differs in that the labeling only utilizes heavy amino acids. The use of only heavy amino acids eliminates the need for 100% incorporation of amino acids needed for SILAC. The increased multiplexing capability of NeuCode amino acids is from the use of mass defects from extra neutrons in the stable isotopes. These small mass differences however need to be resolved on high resolution mass spectrometers. One of the main benefits of SILAC is the level of quantitation bias from processing errors is low because heavy and light samples are combined before sample preparation for MS analysis. SILAC and NeuCode SILAC are excellent techniques for detecting small changes in protein levels or post-translational modifications between experimental groups.
On 24 February 2022, Russia launched a full-scale invasion of Ukraine, occupying large parts of the country and unilaterally declaring the annexation of southeastern Ukraine in September that year. Soon after, journalist H. D. S. Greenway cited the Russian invasion of Ukraine and 4 February joint statement between Russia and China (under Putin and Xi Jinping) as one of the signs that Cold War II had officially begun. Jaro Bilocerkowycz, Associate Professor of Political Science at the University of Dayton, wrote that the invasion of Ukraine could be the start of a "new Cold War", placing Ukraine "at the center of a geopolitical struggle reminiscent of the Cold War days when Germany and its capital city Berlin were split in two". In March 2022, Harvard historian Fredrik Logevall asserted that the conflict over Ukraine was "fundamentally different from the Cold War" because it did not have the "massive arms race and a general absence of diplomacy, and a deep ideological schism". Yale historian Arne Westad agreed and said that Putin's statements about Ukraine resembled late 19th- and early 20th-century colonial and imperial ideas, rather than those of the Cold War. In June 2022, journalist Gideon Rachman asserted the Russian invasion of Ukraine as the start of a second Cold War. In response to US plans to deploy long-range missiles in Germany, including SM-6 and Tomahawk cruise missiles and developmental hypersonic weapons, Putin stated in July 2024 that the situation was reminiscent of the Cold War.
Following his death, Logan appears posthumously in two recordings - the first for the assisted living community Living+ and the second an archival recording of a dinner party with his employees and Connor, of which his children Kendall, Roman, and Shiv become emotional upon viewing.
=== Stages of healing === The graft is carefully spread on the bare area to be covered. It is held in place by a few small stitches or surgical staples. The healing process for skin grafts typically occurs in three stages: plasmatic imbibition, capillary inosculation, and neovascularization. During the first 24 hours, the graft is initially nourished by a process called plasmatic imbibition in which the graft "drinks plasma" (i.e., absorbs nutrients from the underlying recipient bed). Between 2 and 3 days, new blood vessels begin growing from the recipient area into the transplanted skin in a process called capillary inosculation. Between 4 and 7 days, neovascularization occurs in which new blood vessels form between the graft and the recipient tissues.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.